In addition, GEM decreased the uptake of 18F-FDG in the GEM-R-hENT1 group compared with the GEM-R group (mean SUVmax of 1.063 ± 0.21 vs. 2.733 ± 0.81, p < 0.01), suggesting that hENT1 overexpression reversed cancer drug resistance in vivo (Fig. 6D). Here, SLC29A1 is linked to cancer.